[1059] Digital biomarker discovery for precision oncology

The integration of clinical biomarkers into therapeutic strategies in oncology allows healthcare professionals to select the most appropriate therapies for each patient, taking into account their unique genetic and molecular profiles. This significantly improves treatment outcomes by offering a more personalized therapeutic approach while reducing the likelihood of ineffective interventions. In our group, we utilize various data sources such as digital pathology, radiology, genomics as well as clinical and molecular data, to develop actionable biomarkers for various oncological treatments. Our goal is to use large-scale multimodal data and provide approaches that leverage the power of artificial intelligence, in order to better guide clinical decisions and bring benefit to patients. Our current research focuses primarily on the development of biomarkers to assess and predict response to immuno-oncological treatments, such as immune checkpoint inhibitors.